What is Cytena?
CYTENA is an award-winning biotechnology company specializing in user-friendly single-cell dispensers and fully automated solutions designed to streamline cell line development workflows. Their advanced technology accelerates the creation of stable cell lines crucial for therapeutic antibodies, viral vectors, and cell therapies. Serving a global clientele of biopharmaceutical companies, biotechs, and CDMOs, CYTENA's solutions are instrumental in modernizing therapy development, making the process faster, safer, and more cost-effective. As part of the BICO group, CYTENA is dedicated to advancing lab automation within the life sciences.
How much funding has Cytena raised?
Cytena has raised a total of $3.6M across 2 funding rounds:
Angel/Seed
$1.2M
Series A
$2.4M
Angel/Seed (2015): $1.2M with participation from High-Tech Gru00fcnderfonds
Series A (2019): $2.4M, investors not publicly disclosed
Key Investors in Cytena
High-Tech Gründerfonds
High-Tech Gründerfonds is a prominent German venture capital firm that invests in high-potential technology startups. Their focus typically lies in early-stage companies across various tech sectors, including life sciences and biotechnology.
What's next for Cytena?
With the recent major strategic investment, CYTENA is poised for significant advancements in its mission to automate cell line development. This capital infusion, part of its {{totalFundingContext}}, will likely support the scaling of its operations, further research and development into next-generation single-cell dispensing technologies, and expansion into new therapeutic areas. The company's integration within the BICO group provides a strong foundation for synergistic growth and market penetration, positioning CYTENA to capitalize on the increasing demand for efficient and reliable bioprocessing solutions in the biopharmaceutical industry.
See full Cytena company page
